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Abstract 
Review on PDGFRA, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Keywords 
tyrosine kinase, intracellular signaling, 
transmembrane receptor protein tyrosine kinase 
activity. 
Identity 
Other names: CD140A, PDGFR-2, PDGFR2, 
RHEPDGFRA 
HGNC (Hugo): PDGFRA 
Location: 4q12 
Note 
Size: 69151 bases; Orientation: plus strand. 
DNA/RNA 
Description 
The gene encoding the α-subunit of the PDGFRA 
maps to band q12 of chromosome 4.  
The gene contains 23 exons spanning about 65 kb. 
The first noncoding exon is followed by a large 
intron of approximately 23 kb (Gronwald et al., 
1990; Kawagishi et al., 1995).  
An important paralog of PDGFRA is FLT4. 
Transcription 
6.4-kb transcript; coexpressed with the 5.3-kb 
PDGF receptor mRNA. 
 
Protein 
Description 
Size: 1089 amino acids; molecular weight: 122670 
Da.  
Subunit: Interacts with dimeric PDGFA, PDGFB 
and/or PDGFC; heterodimers with PDGFRB. 
Present in an inactive conformation as a monomer 
in the absence of bound ligand. 
Expression 
PDGFR expression is characteristic of various 
mesodermal derivatives; specially expressed in the 
urinary tracts and in male and female genitals. 
Localisation 
Subcellular location: cell membrane. 
Function 
Member of the type III class of tyrosine kinase 
receptors which also includes c-KIT, FLT3 and the 
macrophage-colony-stimulating factor receptor; 
characterized by five immunoglobuline-like 
extracellular domains; a single-spanning 
transmembrane domain and an intracellular split 
kinase domain, connected by a flexible polypeptide 
insert; structurally homologous to c-KIT. PDGFA 
has transmembrane receptor protein tyrosine kinase 
activity and acts as a cell-surface receptor for 
members of the platelet-derived growth factor 
family: PDGFA, PDGFB and PDGFC, which are 
mitogens for fibroblasts and cells of mesenchymal 
origin origin. It plays an essential role in the 
regulation of many biological processes including 
cell proliferation, survival, differentiation and cell  
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migration. Plays an important role in embryonic 
development, in the adult control tissue 
homeostasis in various organs including kidney, 
epidydimis, lung and pancreas; required for normal 
development of intestinal villi in the gastrointestinal 
tract, plays a role in platelet activation, wound 
healing and angiogenesis (Demoulin et al., 2012; 
Heldin et al., 2013). 
Regulation: Function as homo- and/or heterodimers 
depending on the cell type; activated by ligand-
induced dimerization and autophosphorylation on 
specific tyrosine residues upon binding. Activation 
of the intracellular kinase activity of the receptor 
leads to creation of docking sites for signal 
transduction molecules. Subsequent 
phosphorylation of its substrates initiates a variety 
of signal transduction cascades that promotes cell 
proliferation, survival and migration through the 
PI3K-AKT-mTOR and RAS-MAPK pathways as 
well as promotes activation of STAT family 
members (JAK/STAT) (Demoulin et al., 2012). 
Mutations 
Note 
Mutations in the PDGFRA gene contribute to the 
pathophysiology of various diseases such as 
atherosclerosis, abnormalities of the tubal neural 
development and fibrotic diseases. In cancer, 
activating point mutations, gene amplifications and 
chromosomal rearrangements including gene 
fusions and chromosomal deletions have been 
found in certain malignancies. These include 
hematological malignancies such as acute myeloid 
leukemia, atypical chronic myelogenous leukemia, 
chronic myelomonocytic leukemia, eosinophilic 
disorders and mastocytosis (Gotlib et al., 2008).  
PDGFRA mutations also have been described in 
somatic and familial gastrointestinal stromal 
tumors, synovial sarcomas, glioblastoma, malignant 
peripheral nerve sheath tumors, melanoma and a in 
a variety of other cancers (Chompret et al., 2004; 
Heinrich et al., 2003). 
Implicated in 
Gastrointestinal stromal tumor (GIST) 
Note 
Activating mutations of PDGFRA are found in 5-
8% of patients with gastrointestinal stromal tumors 
(GISTs) but their frequency increases to 30% to 
40% in gastric GISTs lacking KIT mutations 
(Corless et al., 2005; Lasota et al., 2008). The 
majority of these mutations are "substitution 
missense", that can arise by various mechanisms 
(Figure 1).  
These include mutation hot spots in exon 18 of the 
PDGFRA gene such as the Asp-to-Val substitution 
at codon 842 (D842V) encoding the activation loop. 
Other activating mutations are less frequent such as 
mutations in exons 12 encoding the juxtamembrane 
domain and in exon 14 encoding the tyrosine kinase 
1 domain of PDGFRA (Chompret et al., 2004; 
Heinrich et al., 2003).  
PDGFRA mutations except for D842V in exon 18 
are sensitive to imatinib inhibition.  
However, despite initial clinical responses to 
tyrosine kinase inhibitors (imatinib, nilotinib, 
sorafenib and sunatinib), the majority of these 
patient develops resistance to the drug limiting the 
long-term benefit of tyrosine kinase inhibitors in 
this group of patients (Gramza et al., 2009; Pierotti 
et al., 2011). 
 
 
Figure 1. Schematic representation of the most frequent activating mutations of the homologous platelet-derived 
growth factor receptor alpha (PDGFRA) kinase in patients with gastrointestinal stromal tumors. Most common mutations 
are in exon 18, such as the D842V substitution that shows resistance to imatinib. Mutations in the juxtamembrane domain (exon 
12; V561D most common) and in exon 14 tyrosine kinase 1 (TK1) domain (e.g., N659K) are less common. Abbreviations: JM, 
juxtamembrane; TK, tyrosine kinase. Adopted and modified from Pierott et al., 2011). 
PDGFRA (platelet-derived growth factor receptor, alpha 
polypeptide) 
Zamecnikova A, Al Bahar S 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(3) 196 
 
Figure 2. The structure and mechanism of activation of PDGFRA fusions in hematological disorders. In the fusion 
oncogene, the partner gene always replaces the 5 part of exon 12 of PDGFRA creating an in frame fusion. As the 5 part of exon 
12 of PDGFRA containing the inhibitory domain is truncated, its expression is controlled by the partner gene promoter resulting 
in constitutive activation of the PDGFRA kinase domain. NH2: N-terminal site; COOH: C-terminal site; TM: transmembrane 
domain; JM: juxtamembrane domain. Adopted and modified from Cools et al., 2003 and Gotlib et al., 2008). 
 
 
The D842V mutation results in an amino acid 
substitution at position 842 in PDGFRA, from an 
aspartic acid (D) to a valine (V).  
This mutation occurs within the TK2 domain 
(Figure 1). 
PDGFRA D842V mutation has been found in a 
distinct subset of GIST, typically from the stomach. 
The D842V mutation is known to be associated 
with tyrosine kinase inhibitor resistance. 
Hematologic disorders with primary 
eosinophilia 
Note 
Several chromosomal rearrangements generating 
fusion genes causing PDGFRA activation have 
been described in a variety of uncommon 
hematologic disorders that are often accompanied 
with a related condition called hypereosinophilic 
syndrome.  
These rearrangements activate PDGFRA by fusion 
to various partner genes: STRN (2p24) in the 
t(2;4)(p22;q12), FIP1L1 (interstitial 4q12 deletion), 
CDK5RAP2 (9q33) in the ins(9;4)(q33;q12q25), 
KIF5B (10p11) in the t(4;10)(q12;p11), ETV6 
(12p13) in the t(4;12)(q12;p13), and BCR (22q11) 
in the t(4;22)(q12;q11).  
In each of these rearrangements, the breakpoints in 
PDGFRA partner genes are variable, but the 
breakpoints in PDGFRA invariably involve exon 12 
encoding a portion of the juxtamembrane domain 
with autoinhibitory function (Baxter et al., 2002; 
Gotlib et al., 2008); the disruption of which 
activates the fusion protein (Figure 2). 
The most investigated of these fusion genes is 
FIP1L1-PDGFRA that arise as a result of a cryptic 
interstitial deletion on chromosome 4q12. FIP1L1-
PDGFRA fusion protein is involved in the 
pathogenesis of uncommon hematologic disorders 
with primary eosinophilia like chronic eosinophilic 
leukemia (CEL) hyperseosinophilic syndrome 
(HES) and systemic mastocytosis (SM). Similar to 
other fusion tyrosine kinases, FIP1L1-PDGFRA is 
a constitutively active tyrosine kinase that was 
shown to be sensitive to kinase inhibitors (Cools et 
al., 2003; Jain et al., 2013). 
Lung adenocarcinoma 
Cytogenetics 
A t(4;12)(q12;q12) was found in a case of lung 
adenocarcinoma (Seo et al., 2012). 
Hybrid/Mutated gene 
SCAF11/PDGFRA 
Breakpoints 
See figure below. 
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